Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Cecoureterocele Presenting as a Urethral Mass in an Infant Female: A Rare Case Report.

Biomedicine hub·2026

Same author

Clinico-Radiological Outcomes of Arthroscopic Rotator Cuff Repair With a Single-Row Construct Supplemented With Bone Marrow Vents.

Cureus·2026

Same author

Artificial intelligence for fall detection in older adults: A comprehensive survey of machine learning, deep learning approaches, and future directions.

Ageing research reviews·2025

Same author

Extraperitoneal Robot-Assisted Kidney Transplant: Initial Experience and Propensity-Matched Comparison with Transperitoneal RAKT.

Journal of endourology·2025

Same author

Novel approach to reduce rewarm ischemia time in triple-vessel robot-assisted kidney transplant using internal iliac artery graft.

Indian journal of urology : IJU : journal of the Urological Society of India·2025

Same author

Steroidal glycoside-rich extract of fenugreek seeds mitigates obesity-induced insulin resistance via attenuation of low-grade inflammation.

Food research international (Ottawa, Ont.)·2025

Search research articles

Related Experiment Video

Updated: Jun 6, 2025

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Personalized cancer vaccine design using AI-powered technologies.

Anant Kumar¹, Shriniket Dixit², Kathiravan Srinivasan²

¹School of Bioscience and Technology, Vellore Institute of Technology, Vellore, India.

Frontiers in Immunology

|November 25, 2024

Summary

Artificial intelligence (AI) is revolutionizing cancer vaccine development by enabling precise epitope design and personalized strategies. AI integration promises more effective cancer immunotherapies, though challenges like tumor heterogeneity and ethical concerns require further attention.

Keywords:

MHCpeptide binding prediction artificial intelligence cancer vaccine epitope design neoantigen prediction nucleic acid cancer vaccines peptide cancer vaccines personalized cancer vaccine

More Related Videos

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

Related Experiment Videos

Last Updated: Jun 6, 2025

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

Area of Science:

Oncology
Immunology
Bioinformatics

Background:

Cancer immunotherapy, particularly cancer vaccines, offers a promising approach to combatting cancer, a leading global cause of mortality.
While historically prophylactic, therapeutic cancer vaccines targeting tumor-associated antigens (TAAs) and neoantigens are advancing treatment possibilities.

Purpose of the Study:

To review the transformative role of artificial intelligence (AI) in enhancing the design, delivery, and personalization of cancer vaccines.
To explore how AI facilitates epitope identification, optimizes vaccine constructs (mRNA, DNA), and predicts patient responses for improved therapeutic efficacy.

Main Methods:

Review of current literature on AI applications in cancer vaccine development.
Analysis of AI's role in epitope prediction, vaccine vector optimization, and personalized treatment strategy formulation.
Discussion of challenges and future directions in AI-driven cancer vaccine research.

Main Results:

AI significantly enhances precision in epitope design and neoantigen prediction, crucial for therapeutic vaccine development.
AI optimizes mRNA and DNA vaccine instructions and enables personalized vaccine strategies by predicting individual patient responses.
AI integration aids in navigating complex biological data to identify novel therapeutic targets, improving cancer vaccine efficacy.

Conclusions:

AI is pivotal in advancing personalized cancer immunotherapies, moving towards more targeted and effective cancer treatments.
Addressing challenges such as tumor heterogeneity, genetic variability, and ethical considerations is essential for the responsible deployment of AI in cancer vaccine development.
Interdisciplinary collaboration and continuous innovation are key to overcoming hurdles and realizing the full potential of AI-powered cancer vaccines.